Zusammenfassung
Neuroblastome zeigen ein sehr heterogenes Bild und können sich vom gutartigen Tumor, der sich spontan zurückbildet, bis zum foudroyant verlaufenden Tumor präsentieren. Mehr als die Hälfte der Neuroblastome müssen als Hochrisikotumoren klassifiziert werden, mit einer ausgesprochen hohen Rezidivrate. Die Überlebensrate von Kindern mit einem Neuroblastom liegt trotz multimodaler Therapie bei unter 40%. Durch internationale Multicenterstudien seit den frühen 70er Jahren des vorigen Jahrhunderts liegen immer mehr Daten vor, die zu einer neuen Betrachtung der Diagnosestellung, des Stagings, der Tumorbiologie und -pathologie und des therapeutischen Vorgehens führen.
Abstract
Neuroblastomas have a very heterogenic clinical presentation, ranging from relatively benign forms with the potential of spontaneous regression, to foudroyant malignant forms. Over half of neuroblastomas must be classified as high-risk tumors with a markedly high rate of recurrence. Despite multidisciplinary therapeutic approaches, the survival rate of children with this type of tumor is still below 40%. An ever-growing amount of data from international studies dating from the early 1970s onwards, points to the necessity of re-evaluating the medical approach in establishing the diagnosis and staging, understanding tumor biology and pathology, as well as therapy planning.
This is a preview of subscription content, log in via an institution to check access.
Literatur
De Bernardi B, Pianca C, Pistamiglio P et al. (2001) Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 19: 183–190
De Bernardi B, Nicolas B, Boni L et al. and the Italian Co-Operative Group for Neuroblastoma (2003) Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 21: 1592–1601
De Bernardi B, Balwierz W, Bejent J et al. (2005) Epidural compression in neuroblastoma: diagnostic and therapeutic aspects. Cancer Lett 228: 283–299
George RE, London WB, Cohn SL et al. (2005) Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 23: 6466–6473
Goo HW, Choi SH, Ghim T et al. (2005) Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol 35: 766–773
Hiorns MP, Owens CM (2001) Radiology of neuroblastoma in children. Eur Radiol 11: 2071–2081
Kaplan SJ, Holbrook CT, McDaniel HG et al. (1980) Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child 134: 21–24
Kushner BH, Yeung HW, Larson SM et al. (2001) Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19: 3397–3405
Mahoney NR, Liu GT, Menacker SJ et al. (2006) Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol 142: 651–659
Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106–2120
Matthay KK, Villablanca JG, Seeger RC et al. (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 341: 1165–1173
Matthay KK, Blaes F, Hero B et al. (2005) Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genova, Italy 2004. Cancer Lett 228: 275–282
McHugh K (2007) Renal and adrenal tumours in children. Cancer Imaging 7: 41–51
Meyer JS, Siegel MJ, Farooqui SO et al. (2005) Which MRI sequence of the spine best reveals bone-marrow metastases of neuroblastoma? Pediatr Radiol (8): 778–785
Nishi M, Miyake H, Takeda T et al. (1987) Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 60: 433–436
Sawada T, Kidowaki T, Sakamoto I et al. (1984) Neuroblastoma. Mass screening for early detection and its prognosis. Cancer 53: 2731–2735
Scanga DR, Martin WH, Delbeke D (2004) Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 29: 86–90
Schilling FH, Spix C, Berthold F et al. (2003) Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer Lett 197: 19–28
Schmidt ML, Lal A, Seeger RC et al. (2005) Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children’s Cancer Group Study. J Clin Oncol 23: 6474–6480
Shimada H, Ambros IM, Dehner LP et al. (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86: 364–372
Woods WG, Gao RN, Shuster JJ et al. (2002) Screening of infants and mortality due to neuroblastoma. N Engl J Med 346: 1041–1046
Woodward PJ, Sohaey R, Kennedy A, Koeller KK (2005) From the archives of the AFIP: a comprehensive review of fetal tumors with pathologic correlation. Radiographics 25: 215–242
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hörmann, M. Neuroblastom im Kindesalter. Radiologe 48, 940–945 (2008). https://doi.org/10.1007/s00117-008-1652-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00117-008-1652-7